149 related articles for article (PubMed ID: 12952258)
1. Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices.
Brand P; Beckmann H; Maas Enriquez M; Meyer T; Müllinger B; Sommerer K; Weber N; Weuthen T; Scheuch G
Eur Respir J; 2003 Aug; 22(2):263-7. PubMed ID: 12952258
[TBL] [Abstract][Full Text] [Related]
2. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
3. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency?
Kropp J; Wencker M; Hotze A; Banik N; Hübner GE; Wunderlich G; Ulbrich E; Konietzko N; Biersack HJ
J Nucl Med; 2001 May; 42(5):744-51. PubMed ID: 11337570
[TBL] [Abstract][Full Text] [Related]
4. Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) - problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis.
Siekmeier R
Eur J Med Res; 2010 Nov; 15 Suppl 2(Suppl 2):164-74. PubMed ID: 21147646
[TBL] [Abstract][Full Text] [Related]
5. Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis.
Häussermann S; Winnips C; Edelman J; Kappeler D; Herpich C; Ehlich H; Zanker D; Kietzig C; Sommerer K
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):242-50. PubMed ID: 26669827
[TBL] [Abstract][Full Text] [Related]
6. [Difficulties in controlled inhalation of alpha 1-protease inhibitor].
Brand P; Maas Enriquez M; Meyer T; Scheuch G; Weber N
Pneumologie; 2003 Mar; 57(3):153-8. PubMed ID: 12632295
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
Campos MA; Kueppers F; Stocks JM; Strange C; Chen J; Griffin R; Wang-Smith L; Brantly ML
COPD; 2013 Dec; 10(6):687-95. PubMed ID: 23862647
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of Alpha-1 MP (Prolastin
Seyama K; Nukiwa T; Sato T; Suzuki M; Konno S; Takahashi K; Nishimura M; Steinmann K; Sorrells S; Chen J; Hayashi KI
Respir Investig; 2019 Jan; 57(1):89-96. PubMed ID: 30416054
[TBL] [Abstract][Full Text] [Related]
9. Delivery of Alpha-1 Antitrypsin to Airways.
Griese M; Scheuch G
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S346-51. PubMed ID: 27564672
[TBL] [Abstract][Full Text] [Related]
10. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.
Gaggar A; Chen J; Chmiel JF; Dorkin HL; Flume PA; Griffin R; Nichols D; Donaldson SH
J Cyst Fibros; 2016 Mar; 15(2):227-33. PubMed ID: 26321218
[TBL] [Abstract][Full Text] [Related]
11. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira.
Stocks JM; Brantly M; Pollock D; Barker A; Kueppers F; Strange C; Donohue JF; Sandhaus R
COPD; 2006 Mar; 3(1):17-23. PubMed ID: 17175661
[TBL] [Abstract][Full Text] [Related]
12. [Prospective evaluation of clinical parameters of AAT patients with i. v. prolastin therapy in a homecare setting].
Wilke A; Grohé C
Pneumologie; 2013 Oct; 67(10):545-50. PubMed ID: 23999697
[TBL] [Abstract][Full Text] [Related]
13. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency.
Brand P; Schulte M; Wencker M; Herpich CH; Klein G; Hanna K; Meyer T
Eur Respir J; 2009 Aug; 34(2):354-60. PubMed ID: 19251783
[TBL] [Abstract][Full Text] [Related]
14. Human plasma-derived alpha
Lagarde WH; Courtney KL; Reiner B; Steinmann K; Tsalikian E; Willi SM
Pediatr Diabetes; 2021 Mar; 22(2):192-201. PubMed ID: 33244872
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
16. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
17. [Hereditary alpha-1-antitrypsin deficiency can cause COPD. Substitution treatment seems to result in fewer infections and prolonged survival].
Janciauskiene S
Lakartidningen; 2007 Nov 28-Dec 4; 104(48):3631-4, 3637-8. PubMed ID: 18193673
[No Abstract] [Full Text] [Related]
18. [Lack of effect of substitution therapy of alpha1-antitrypsin deficiency].
Dahl R; Hilberg O; Løkke A; Pedersen L; Ringbæk T; Titlestad I
Ugeskr Laeger; 2011 Oct; 173(42):2645-7. PubMed ID: 22027165
[TBL] [Abstract][Full Text] [Related]
19. The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.
Geller DE; Kesser KC
J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23 Suppl 1(Suppl 1):S55-9. PubMed ID: 20373910
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
